No recent public news or analyst coverage is available for Odyssey Therapeutics, Inc. as of the report date.

• The company announced its financial results for the quarter ended March 31, 2026, reporting a net loss of $38.3 million and strong liquidity ratios as per its 10-Q filing on June 17, 2026.[S1]
• Odyssey Therapeutics completed its IPO and a concurrent private placement financing in May 2026, amending its corporate governance documents accordingly.[S1]

The company has demonstrated strong liquidity with a current ratio above 8, indicating a solid financial position to support ongoing research and development activities. The successful completion of an IPO and private placement financing reflects investor support and access to capital. These factors may enable the company to advance its clinical programs and potentially achieve regulatory milestones.

Odyssey Therapeutics reported a significant net loss of $38.3 million for the most recent quarter, reflecting the high costs typical of clinical-stage biopharmaceutical companies without commercial products. The lack of disclosed revenue and product details increases uncertainty about the company's path to profitability. Additionally, the absence of recent news or analyst coverage limits external validation of its business progress or market potential.

Odyssey Therapeutics operates in the biopharmaceutical sector, which typically requires significant investment in research and development, regulatory approvals, and intellectual property protections. While specific competitive advantages or proprietary technologies are not disclosed, the company's ability to secure institutional investment and complete an IPO suggests some level of investor confidence in its scientific or technological platform. However, the absence of detailed product or pipeline information limits assessment of its moat.

• Clinical and Regulatory Risk: As a clinical-stage biopharmaceutical company, Odyssey Therapeutics faces risks related to the successful development, testing, and regulatory approval of its product candidates.
• Financial Risk: The company reported a net loss and relies on capital markets and investor funding to finance operations, which may be subject to market conditions and dilution risks.
• Operational Risk: Limited public disclosure on business operations and product pipeline increases uncertainty about execution capabilities and timelines.

• Odyssey Therapeutics, Inc. is a Delaware corporation headquartered in Boston, Massachusetts.
• The company completed an initial public offering (IPO) in May 2026 and concurrently closed a private placement financing.
• As of March 31, 2026, Odyssey Therapeutics reported cash and cash equivalents of $35.7 million and short-term investments of $140.0 million, totaling $185.1 million in current assets.
• Current liabilities as of March 31, 2026, were $22.2 million, resulting in a strong current ratio of 8.33 and a cash ratio of 7.91, indicating high liquidity.
• The company reported a net loss of $38.3 million for the quarter ended March 31, 2026, with basic and diluted earnings per share of -$6.77.
• The company is listed on The Nasdaq Stock Market under the ticker ODTX.
• The company has amended and restated its certificate of incorporation and bylaws in connection with the IPO.
• A Share Purchase Agreement was executed in May 2026 with an institutional investor for 1,388,889 shares at the IPO price of $18.00 per share, with registration rights under an investor rights agreement.